Imc-a12 (Not yet branded)

Other Medications

US Experimental EU Experimental ES med_spain_not_available IV 2 Clinical Trials
IGF-1R

Description

IMC-A12 (cixutumumab) is a fully human monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R). In metastatic colorectal cancer, it has been evaluated in combination with cetuximab and irinotecan-based regimens for patients who have progressed on prior treatments. The drug was designed to block IGF-1R signaling pathways that contribute to tumor growth and resistance to EGFR-targeted therapies like cetuximab.

Mechanism of Action

Cixutumumab binds specifically to the insulin-like growth factor-1 receptor (IGF-1R), preventing binding of IGF-1 and IGF-2 ligands. This blockade inhibits downstream PI3K/AKT and MAPK signaling pathways that promote cell proliferation, survival, and metastasis in colorectal tumors.

Molecular Targets

Side Effects

Hyperglycemia Fatigue Decreased appetite Nausea Diarrhea Skin rash Infusion reactions Thrombocytopenia

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00845039 med_phase_prefix2
Archived
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
United States
NCT00503685 med_phase_prefix2
Archived
Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy
United States

Quick Info

Brand NameNot yet branded
CategoryOther Medications
US StatusExperimental
EU Estado EMAExperimental
ES Acceso Españamed_spain_not_available
AdministrationIV
Clinical Trials2
View Clinical Trials Back to Drug Glossary

Related Medications

Ganitumab
Immunotherapy
3 trials
OSI-906
Other Medications
3 trials
AMG-655
Other Medications
3 trials
Dalotuzumab
Immunotherapy
3 trials
AMG-479
Other Medications
3 trials
Uracil
Other Medications
767 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.